← back to search

Zhihao Lü

Nanjing Tech University · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, and Colorectal Cancer Treatments and Studies.
h-index
33
citations
5,255
works
203
NIH funding
primary concept
Medicine
email

Recent publications

Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer
Nature Communications 2024cited by 29position: middledoi
SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
Journal of Clinical Oncology 2024cited by 28position: middledoi
LSFSR: Local label correlation-based sparse multilabel feature selection with feature redundancy
Information Sciences 2024cited by 17position: middledoi
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
EClinicalMedicine 2024cited by 9position: firstdoi
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
The Lancet Oncology 2023cited by 190position: middledoi
Pangenome analysis provides insight into the evolution of the orange subfamily and a key gene for citric acid accumulation in citrus fruits
Nature Genetics 2023cited by 156position: middledoi
CACA guidelines for holistic integrative management of esophageal carcinoma
Holistic Integrative Oncology 2023cited by 12position: middledoi
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
Journal of Clinical Oncology 2023cited by 8position: firstdoi
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
BMJ 2022cited by 470position: firstdoi
The high-quality genome of pummelo provides insights into the tissue-specific regulation of citric acid and anthocyanin during domestication
Horticulture Research 2022cited by 30position: firstdoi
Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
The Innovation 2022cited by 15position: firstdoi
Somatic variations led to the selection of acidic and acidless orange cultivars
Nature Plants 2021cited by 135position: middledoi
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Nature 2020cited by 335position: firstdoi
Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial
Clinical Cancer Research 2020cited by 112position: middledoi
Complete mitochondrial genome of the witch-hazel leaf gall aphid <i>Hamamelistes spinosus</i> (Hemiptera: Aphididae: Hormaphidinae)
Mitochondrial DNA Part B 2020cited by 4position: firstdoi
Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis
Cancer Cell 2019cited by 190position: middledoi
[Mechanism of <i>Shenbing decoction</i> Ⅲ in the treatment of proteinuria in chronic kidney disease: a network pharmacology-based study].
PubMed 2019cited by 6position: middledoi
A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
Gastric Cancer 2018cited by 58position: firstdoi
Acid-promoted iron-catalysed dehydrogenative [4 + 2] cycloaddition for the synthesis of quinolines under air
RSC Advances 2018cited by 16position: middledoi
144O Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study
Annals of Oncology 2015cited by 1position: middledoi
P-0042 Preliminary Safety Analysis From PAC-C Study of Capecitabine+Paclitaxel→Capecitabine Maintenance (PX-X) vs Capecitabine+Cisplatin (XP) As First-Line Chemotherapy for Recurrent/Metastatic Gastric Cancer
Annals of Oncology 2012cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Lin Shen · Qinghai University5 papers (2012–2024)Tianshu Liu · Sun Yat-sen University3 papers (2012–2024)Qingxia Fan · First Affiliated Hospital of Zhengzhou University3 papers (2012–2024)Yueyin Pan · University of Science and Technology of China3 papers (2012–2022)Qiang Xu · Massachusetts Eye and Ear Infirmary2 papers (2021–2022)Wei Bai · Ministry of Education of the People's Republic of China2 papers (2015–2018)Yongqian Shu · Suzhou Municipal Hospital2 papers (2015–2018)Yanqiao Zhang · Zhejiang Provincial People's Hospital2 papers (2022–2023)Yuxian Bai · Harbin Medical University2 papers (2015–2018)Wěi Li · Beijing Tongren Hospital2 papers (2012–2018)Xiaotian Zhang · Renji Hospital2 papers (2012–2018)Wei Liu · Hebei Medical University2 papers (2012–2018)Lin Shen · Beijing Tongren Hospital2 papers (2022–2023)Nong Xu · Hangzhou First People's Hospital2 papers (2012–2018)Lun Wang · Ningbo University2 papers (2021–2022)Yue Huang · University of Illinois Chicago2 papers (2021–2022)Yueyuan Zheng · Guangzhou University of Chinese Medicine1 papers (2024–2024)Yuan‐Wei Zhang · Guangzhou University1 papers (2024–2024) · 1 papers (2024–2024)Xiaolin Jiang · Guangzhou University of Chinese Medicine1 papers (2021–2021)